Virtual care offers a significant opportunity to bridge the gap between supply and demand in behavioral health services. However, there are risks associated with the lack of integration between virtual care and traditional healthcare systems, particularly in medication management.
Sanjula Jain, Ph.D., chief research officer at Trilliant recently spoke with Managed Healthcare Executive about the distinct role of virtual care, particularly in behavioral health.
Based off of recent studies published by Trilliant Health, Jain pointed out that virtual care is most effective for "low acuity behavioral health" and stressed the importance of differentiating between long-term care delivery relationships and more transactional, direct-to-consumer models.
Virtual care offers a significant opportunity to bridge the gap between supply and demand in behavioral health services, she shared. However, there are risks associated with the lack of integration between virtual care and traditional healthcare systems, particularly in medication management.
Related: Research Finds Virtual Care as Convenient but May Fail to Build Long-Term Patient Connections
“There is probably more focus on the care delivery relationship piece that providers should really be thinking about when it comes to medication management,” she said.
She also suggested that virtual care could be used to identify comorbidities and create referral relationships for higher acuity needs but noted it’s a broader challenge not limited to virtual care alone.
Related: Hospitals Should Consider Clinical Use, Payment Parity When Investing in Telehealth Post-Pandemic
Jain told MHE editors she sees virtual care as a tool with the potential to enhance patient engagement and access to necessary services, though it requires careful implementation to ensure comprehensive care.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More